Faron Pharmaceuticals Oy (HEL:FARON)
Finland
· Delayed Price · Currency is EUR | Market Cap | 75.17M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -30.95M |
| Shares Out | n/a |
| EPS (ttm) | -0.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 661,468 |
| Average Volume | 1,907,313 |
| Open | 0.630 |
| Previous Close | 0.626 |
| Day's Range | 0.588 - 0.640 |
| 52-Week Range | 0.492 - 3.345 |
| Beta | 1.35 |
| RSI | 23.93 |
| Earnings Date | Mar 4, 2026 |
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company... [Read more]
Financial Performance
Financial StatementsNews
Faron Pharmaceuticals To Earn Spotlight At IUIS 2025 With Its Bexmarilimab Data
At IUIS 2025, Dr. Mika Kontro, MD, PhD, will deliver a presentation titled "Efficacy of Macrophage Checkpoint Clever-1 Inhibition with bexmarilimab plus Azacitidine in Myelodysplastic Syndrome: Result...